Chief executive Justin Gover said production in 2015 had already increased by 20 times and that this was expected to double further in 2016 to meet "significant" commercial demand for Epidiolex, if it is approved by the US Food and Drug Administration. Some analysts believe the drug could get the green light in early 2017.